6U85 image
Deposition Date 2019-09-04
Release Date 2019-11-13
Last Version Date 2024-10-30
Entry Detail
PDB ID:
6U85
Keywords:
Title:
Site-specific lysine arylation as an alternative bioconjugation strategy for chemically programmed antibodies and antibody-drug conjugates
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.78 Å
R-Value Free:
0.25
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 65
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Antibody Fab heavy chain
Chain IDs:A (auth: H)
Chain Length:221
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:antibody Fab Light chain
Chain IDs:B (auth: L)
Chain Length:219
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates.
Bioconjug.Chem. 30 2889 2896 (2019)
PMID: 31675216 DOI: 10.1021/acs.bioconjchem.9b00609

Abstact

By exploiting a uniquely reactive lysine residue (Lys99) for site-specific attachment of small molecules, the humanized catalytic antibody h38C2 has been used as bioconjugation module in the assembly of chemically programmed antibodies and antibody-drug conjugates. Treatment of h38C2 with β-lactam-functionalized small molecules has been previously shown to result in covalent conjugation by selective formation of a stable amide bond with the ε-amino group of the Lys99 residue. Here we report that heteroaryl methylsulfonyl (MS-PODA)-functionalized small molecules represent an alternative bioconjugation strategy through highly efficient, site-specific, and stable arylation of the Lys99 residue. A set of chemically programmed antibodies and antibody-drug conjugates assembled by Lys99 arylation provided proof-of-concept for the therapeutic utility of this alternative bioconjugation strategy. While being equally effective as β-lactam-functionalized ligands for bioconjugation with catalytic antibody h38C2, the MS-PODA moiety offers distinct synthetic advantages, making it highly attractive.

Legend

Protein

Chemical

Disease

Primary Citation of related structures